Currently Viewing:
Newsroom
Currently Reading
Pembrolizumab as First-Line Treatment Significantly Improves Overall Survival in NSCLC Trial
April 09, 2018 – Jaime Rosenberg
Pembrolizumab Combination Fails to Meet Primary Endpoint in Melanoma Study
April 06, 2018 – Jaime Rosenberg
This Week in Managed Care: April 6, 2018
April 06, 2018
Screening for Multiple Myeloma Precursor Can Reduce Mortality and Slow Progression
April 05, 2018 – Laura Joszt
What We're Reading: 2018 ACA Enrollment; Spread of Rare Superbug; Off-the-Shelf CAR T Therapies
April 04, 2018 – AJMC Staff
Insight Into ASCO's Evaluation of Clinical Pathway Vendors
April 02, 2018 – Jaime Rosenberg
This Week in Managed Care: March 30, 2018
March 30, 2018
AJMC® in the Press, March 30, 2018
March 30, 2018 – AJMC Staff
5 Takeaways From the National Comprehensive Cancer Network's 23rd Annual Conference
March 30, 2018 – Kelly Davio

Pembrolizumab as First-Line Treatment Significantly Improves Overall Survival in NSCLC Trial

Jaime Rosenberg
Pembrolizumab (Keytruda) monotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) met its primary endpoint of overall survival in the Phase 3 KEYNOTE-042 trial when compared with standard of care platinum-based chemotherapy.
Pembrolizumab (Keytruda) monotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) met its primary endpoint of overall survival (OS) in the Phase 3 KEYNOTE-042 trial, announced Merck in a press release.

An interim analysis by the independent Data Monitoring Committee (DMC) determined that pembrolizumab monotherapy yielded significantly improved OS when compared with platinum-based chemotherapy in patients with a PD-L1 tumor proportion score (TPS) of 1% or higher. The trial sequentially tested OS in patients with a TPS of 50% or higher, a TPS of 20% or higher, and then in the entire study cohort with a TPS of 1% or higher; significantly improved OS was continuously demonstrated for pembrolizumab.

“Improvement in overall survival is the ultimate objective in the treatment of advanced lung cancer,” said Tony Mok, MD, professor in the Department of Clinical Oncology at the Chinese University of Hong Kong. “KEYNOTE-042 is the first randomized Phase 3 study of a single-agent immunotherapy using overall survival as the primary endpoint that has demonstrated significant benefit as first-line therapy in NSCLC patients who tested positive for PD-L1 at 1% or higher.”

The trial will continue to evaluate pembrolizumab’s effect on progression-free survival, the study’s secondary end point, based on the recommendation of DMC. The international, open-label, Phase 3 KEYNOTE-042 study enrolled 1274 patients, randomized 1:1, to receive pembrolizumab or standard of care platinum-based chemotherapy. Patients had no EGFR or ALK genomic tumor aberrations and no previous treatment with systematic therapy for advanced disease. 

According to the press release, the demonstrated safety profile of pembrolizumab was consistent with previously reported monotherapy studies involving patients with advanced NSCLC.

“With KEYNOTE-042, Keytruda has now shown a significant survival benefit compared with chemotherapy for patients with locally advanced or metastatic nonsquamous or squamous NSCLC expressing PD-L1 at 1% of higher by tumor proportion score,” said Roger M. Perlmutter, MD, president, Merck Research Laboratories, in a statement. “Keytruda is a foundational treatment for NSCLC and has consistently demonstrated a survival benefit as monotherapy, or in combination with chemotherapy, in the treatment of metastatic lung cancer.”

Pembrolizumab currently has indications for melanoma, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, and gastric cancer. Last month, the FDA accepted a new supplemental Biologics License Application and granted Priority Review for pembrolizumab for the treatment of advanced cervical cancer, marking the 14th regulatory submission accepted by the FDA for the anti-PD-1 therapy.

Related Articles

Pembrolizumab Plus Chemotherapy Approved for Metastatic Nonsquamous NSCLC
Pembrolizumab Shows Promise for Advanced Esophageal Cancer
Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer
Pembrolizumab Granted Priority Review for Treatment of Cervical Cancer
Pembrolizumab Combination Fails to Meet Primary Endpoint in Melanoma Study
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up